Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases

Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases

Vaccines are pivotal for control of the coronavirus disease (COVID-19) pandemic. Patients with inflammatory bowel diseases (IBDs) treated with antitumor necrosis factor (TNF)-α have lower serologic response after two COVID-19 vaccine doses. Data regarding a third vaccine dose are scarce. An Israeli...

Full description

Bibliographic Details
Main Authors: Hadar Edelman-Klapper, Keren Masha Rabinowitz, Eran Zittan, Ariella Bar-Gil Shitrit, Idan Goren, Irit Avni-Biron, Jacob E. Ollech, Lev Lichtenstein, Hagar Banai-Eran, Henit Yanai, Yifat Snir, Maor H. Pauker, Adi Friedenberg, Adva Levy-Barda, Yelena Broitman, Haim Ben Zvi, Tsachi-Tsadok Perets, Rami Eliakim, Revital Barkan, Sophy Goren, Dani Cohen, Iris Dotan
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Vaccines
Subjects:
COVID-19
anti-TNFα
inflammatory bowel diseases
BNT162b2 vaccine
Online Access:https://www.mdpi.com/2076-393X/11/7/1263

Internet

https://www.mdpi.com/2076-393X/11/7/1263

Similar Items